Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.66 |
| ▸ | HPGD | P15428 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.66 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.66 |
| ▸ | MAOA | P21397 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 3/20 | 0.66 |
| ▸ | MPO | P05164 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | TNKS | O95271 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | BCHE | P06276 | 2/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311162 | 0.88 | MAPT (0.66) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL311705 | 0.86 | POLH (0.66) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL312877 | 0.83 | HPGD (0.66) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL909624 | 0.81 | QPCT (1.00) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL31167385 | 0.80 | CYP3A4 (1.00) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL157723 | 0.80 | CYP3A4 (1.00) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL312139 | 0.79 | MAPT (0.66) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL29773081 | 0.78 | TNKS (1.00) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL127446 | 0.78 | TNKS (1.00) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL31238388 | 0.78 | MAPT (0.78) | QPCTCYP3A4HPGDKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | claimed |
| EP-1838296-B1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP (CA) | 2012-08-08 | — | — | EP | claimed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | claimed |
| EP-2332527-A2 | Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2011-06-15 | — | — | EP | claimed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | claimed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | claimed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | claimed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | claimed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | claimed |
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| EP-1838296-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045096-A2 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | QPCT 2445/4885CYP3A4 1730/4885HPGD 138/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | QPCT 2445/4885CYP3A4 1730/4885HPGD 138/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | QPCT 852/4885CYP3A4 3630/4885HPGD 371/4885 |
| US-20130281396-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BCOR, BMI1, PHKB | QPCT 3677/4885CYP3A4 4691/4885HPGD 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.